id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-E-0087-0014,FDA,FDA-2009-E-0087,Letter from U.S. Patent and Trademark Office to Zoetis LLC,Other,Letter(s),2014-04-02T04:00:00Z,2014,4,2014-04-02T04:00:00Z,,2014-04-02T13:07:20Z,,0,0,090000648169763e
FDA-2009-E-0087-0013,FDA,FDA-2009-E-0087,U.S. Patent and Trademark Office to Zoetis - Letter,Other,Letter(s),2013-12-24T05:00:00Z,2013,12,2013-12-24T05:00:00Z,,2013-12-24T13:04:38Z,,0,0,09000064814d407b
FDA-2009-E-0087-0012,FDA,FDA-2009-E-0087,U.S. Patent and Trademark Office to Zoetis Inc. - Letter,Other,Letter(s),2013-11-04T05:00:00Z,2013,11,2013-11-04T05:00:00Z,,2013-11-04T19:06:32Z,,0,0,090000648146f83f
FDA-2009-E-0087-0011,FDA,FDA-2009-E-0087,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-09-18T04:00:00Z,2013,9,2013-09-18T04:00:00Z,,2013-09-18T18:34:30Z,,0,0,090000648142a483
FDA-2009-E-0087-0010,FDA,FDA-2009-E-0087,"U.S. Patent & Trademark Office to Pfizer, Inc. - Letter",Other,Letter(s),2012-07-24T04:00:00Z,2012,7,2012-07-24T04:00:00Z,,2012-07-24T19:29:13Z,,0,0,09000064810acf66
FDA-2009-E-0087-0009,FDA,FDA-2009-E-0087,"FDA/CDER to Pfizer, Inc. - Letter",Other,Letter(s),2012-06-04T04:00:00Z,2012,6,2012-06-04T04:00:00Z,,2012-06-04T18:57:32Z,,0,0,0900006481030a30
FDA-2009-E-0087-0008,FDA,FDA-2009-E-0087,"U.S. Patent & Trademark Office to Pfizer, Inc. - Letter",Other,Letter(s),2012-01-10T05:00:00Z,2012,1,2012-01-10T05:00:00Z,,2012-01-19T16:52:18Z,,0,0,0900006480f90858
FDA-2009-E-0087-0007,FDA,FDA-2009-E-0087,Pfizer Inc. - Letter,Other,Letter(s),2011-07-14T04:00:00Z,2011,7,2011-07-14T04:00:00Z,,2011-07-14T22:27:14Z,,0,0,0900006480ec098a
FDA-2009-E-0087-0006,FDA,FDA-2009-E-0087,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2011-05-04T04:00:00Z,2011,5,2011-05-04T04:00:00Z,,2011-05-04T16:05:50Z,,0,0,0900006480c3f322
FDA-2009-E-0087-0005,FDA,FDA-2009-E-0087,Determination of Regulatory Review Period for Purposes of Patent Extensions; CONVENIA,Notice,N-Notice,2011-04-29T04:00:00Z,2011,4,2011-04-29T04:00:00Z,2011-06-29T03:59:59Z,2011-04-29T14:06:21Z,2011-10379,0,0,0900006480c3be4e
FDA-2009-E-0087-0004,FDA,FDA-2009-E-0087,U.S. Patent and Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2009-12-07T05:00:00Z,2009,12,2009-12-07T05:00:00Z,,2013-07-27T23:01:41Z,,0,0,0900006480a66212
FDA-2009-E-0087-0003,FDA,FDA-2009-E-0087,FDA/CDER to U.S. Patent & Trademark Office - Letter,Other,LET-Letter,2009-09-03T04:00:00Z,2009,9,,,2009-09-03T12:43:04Z,,0,0,0900006480a1bf7c
FDA-2009-E-0087-0002,FDA,FDA-2009-E-0087,Pfizer Inc. - Patent Term Extension Application,Other,APP-Application,2009-02-19T05:00:00Z,2009,2,2009-02-19T05:00:00Z,,2013-08-11T04:31:49Z,,0,0,090000648085f72f
FDA-2009-E-0087-0001,FDA,FDA-2009-E-0087,USPTO to FDA/CDER - Letter,Other,LET-Letter,2009-02-19T05:00:00Z,2009,2,2009-02-19T05:00:00Z,,2009-02-19T13:53:13Z,,0,0,090000648085f6f9